La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Changzhou Qianhong BiopharmaLTD Croissance future
Future contrôle des critères 4/6
Changzhou Qianhong BiopharmaLTD is forecast to grow earnings and revenue by 25.9% and 16% per annum respectively. EPS is expected to grow by 25.8% per annum. Return on equity is forecast to be 14.3% in 3 years.
Informations clés
25.9%
Taux de croissance des bénéfices
25.8%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 18.8% |
Taux de croissance des recettes | 16.0% |
Rendement futur des capitaux propres | 14.3% |
Couverture par les analystes | Low |
Dernière mise à jour | 17 Aug 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Has Affirmed Its Dividend Of CN¥0.12
May 26Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Looks Just Right With A 26% Price Jump
May 21Investors Can Find Comfort In Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Quality
May 02Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?
Mar 24Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 2,562 | 438 | N/A | 464 | 3 |
12/31/2025 | 2,175 | 362 | N/A | 211 | 3 |
12/31/2024 | 1,831 | 303 | N/A | 420 | 3 |
3/31/2024 | 1,667 | 200 | 638 | 733 | N/A |
12/31/2023 | 1,814 | 182 | 433 | 533 | N/A |
9/30/2023 | 2,121 | 253 | 294 | 374 | N/A |
6/30/2023 | 2,223 | 241 | -18 | 56 | N/A |
3/31/2023 | 2,360 | 281 | -261 | -192 | N/A |
1/1/2023 | 2,304 | 323 | -142 | -71 | N/A |
9/30/2022 | 2,155 | 260 | -41 | 42 | N/A |
6/30/2022 | 2,139 | 294 | 37 | 120 | N/A |
3/31/2022 | 2,036 | 255 | 208 | 291 | N/A |
1/1/2022 | 1,875 | 181 | 13 | 104 | N/A |
9/30/2021 | 1,873 | -88 | 23 | 103 | N/A |
6/30/2021 | 1,886 | -107 | 153 | 231 | N/A |
3/31/2021 | 1,913 | -52 | 160 | 233 | N/A |
12/31/2020 | 1,668 | -132 | 255 | 317 | N/A |
9/30/2020 | 1,694 | 188 | 154 | 246 | N/A |
6/30/2020 | 1,487 | 151 | 58 | 155 | N/A |
3/31/2020 | 1,454 | 148 | -33 | 70 | N/A |
12/31/2019 | 1,675 | 263 | 61 | 162 | N/A |
9/30/2019 | 1,462 | 232 | 81 | 196 | N/A |
6/30/2019 | 1,490 | 233 | 25 | 137 | N/A |
3/31/2019 | 1,350 | 227 | -7 | 99 | N/A |
12/31/2018 | 1,322 | 221 | -78 | 25 | N/A |
9/30/2018 | 1,312 | 222 | -85 | -35 | N/A |
6/30/2018 | 1,223 | 202 | -8 | 36 | N/A |
3/31/2018 | 1,160 | 197 | 45 | 90 | N/A |
12/31/2017 | 1,065 | 183 | N/A | 91 | N/A |
9/30/2017 | 995 | 212 | N/A | 123 | N/A |
6/30/2017 | 931 | 226 | N/A | 61 | N/A |
3/31/2017 | 863 | 225 | N/A | 148 | N/A |
12/31/2016 | 776 | 224 | N/A | 221 | N/A |
9/30/2016 | 773 | 250 | N/A | 205 | N/A |
6/30/2016 | 788 | 277 | N/A | 272 | N/A |
3/31/2016 | 750 | 277 | N/A | 292 | N/A |
12/31/2015 | 757 | 267 | N/A | 287 | N/A |
9/30/2015 | 730 | 268 | N/A | 301 | N/A |
6/30/2015 | 744 | 270 | N/A | 292 | N/A |
3/31/2015 | 771 | 259 | N/A | 277 | N/A |
12/31/2014 | 815 | 245 | N/A | 252 | N/A |
9/30/2014 | 807 | 226 | N/A | 240 | N/A |
6/30/2014 | 791 | 205 | N/A | 194 | N/A |
3/31/2014 | 832 | 191 | N/A | 150 | N/A |
12/31/2013 | 861 | 187 | N/A | 160 | N/A |
9/30/2013 | 907 | 188 | N/A | 209 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 002550's forecast earnings growth (25.9% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 002550's earnings (25.9% per year) are forecast to grow faster than the CN market (21.9% per year).
Croissance élevée des bénéfices: 002550's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 002550's revenue (16% per year) is forecast to grow faster than the CN market (13.4% per year).
Croissance élevée des revenus: 002550's revenue (16% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 002550's Return on Equity is forecast to be low in 3 years time (14.3%).